Information Provided By: 
Fly News Breaks for July 27, 2016
MDXG
Jul 27, 2016 | 06:56 EDT
Brean Capital believes Mimedx shares remain undervalued following Q2 earnings. The firm said higher spending cutting into its earnings was a disappointment but at this stage in the company's development they noted the focus is on top-line growth, which remains healthy. Brean Capital reiterated its Buy rating and $12 price target on MiMedx shares.
News For MDXG From the Last 2 Days
There are no results for your query MDXG
